Isarna Therapeutics
Josef-Engert-Strasse 9
Regensburg
D-93053
Germany
Tel: 49-941-9201-30
Fax: 49-941-9201-329
Website: http://www.antisense-pharma.com/
Email: info@antisense-pharma.com
39 articles about Isarna Therapeutics
-
Isarna Therapeutics Presents Update from Phase 2 BETTER Clinical Study in Wet AMD and DME at the EURETINA Meeting
8/31/2022
Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Isarna Therapeutics Announces First Patient Enrolled in International Phase 2a Clinical Study in Ophthalmology Indications Wet AMD and DME
11/30/2021
Isarna Therapeutics announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration and diabetic macular edema.
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Isarna Therapeutics Appoints Claus Schalper as CEO
9/30/2021
Isarna Therapeutics announced the appointment of Claus Schalper as Chief Executive Officer. Mr. Schalper joins Isarna with over 20 years of experience as an executive and serial entrepreneur in the life science and biotech industries.
-
Isarna Therapeutics Presents Positive Clinical Data For ISTH0036 In Advanced Glaucoma And Preclinical Data Supportive Of AMD/DME Potential At ARVO 2017 Annual Conference
5/15/2017
-
Isarna Therapeutics Presents First Interim Phase I Data For ISTH0036 In Advanced Glaucoma At Association for Research in Vision & Ophthalmology 2016 Annual Conference
5/4/2016
-
Isarna Therapeutics And Autotelic Signed Asset Sale And Purchase Agreement For Trabedersen
10/14/2015
-
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome
6/10/2015
-
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma
5/21/2015
-
Isarna Therapeutics Presents Positive Preclinical Results Supporting Development Of ISTH0036 For The Treatment Of Glaucoma
5/11/2015
-
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma
4/16/2015
-
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology
1/8/2015
-
Isarna Therapeutics Raises Euro 5.5 Million, Announces Elizabeth Czerepak Joining As CFO/CBO To Lead U.S. Site
4/24/2014
-
Isarna Therapeutics Enters Into A Strategic Manufacturing Agreement With Sanofi (France)
1/9/2014
-
Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases
1/8/2014
-
Antisense Pharma Changes Name to Isarna Therapeutics
9/30/2013
-
ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen
2/26/2013
-
ANTISENSE PHARMA GmbH Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma
7/24/2012
-
ANTISENSE PHARMA GmbH Presents Trabedersen Phase I/II Complete Data at American Society of Clinical Oncology
6/4/2012